2.60

0.38% -0.010

After Hours: 2.59 -0.01 -0.38%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $2.60, with a volume of 1.38M. It is down -0.38% in the last 24 hours and up +1.56% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$2.61

Open:

$2.59

24h Volume:

1.38M

Relative Volume:

0.77

Market Cap:

$766.13M

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-5.7778

EPS:

-0.45

Net Cash Flow:

$-121.38M

1W Performance:

+4.84%

1M Performance:

+1.56%

6M Performance:

-42.60%

1Y Performance:

-43.48%

1-Day Range:

$2.5845

$2.695

1-Week Range:

$2.43

$2.695

52-Week Range:

$2.335

$6.055

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(604) 559-9005

Address

2215 YUKON STREET, VANCOUVER

Employee

586

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

ABCL's Discussions on Twitter

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Sep 28, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Acquired by Renaissance Technologies LLC - MarketBeat

Sep 28, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Average Price Target from Analysts - MarketBeat

Sep 28, 2024

Sep 27, 2024

Wall Street SWOT: AbCellera stockBiotech firm's platform shows promise amid challenges - Investing.com

Sep 27, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - BioSpace

Sep 27, 2024

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - Midnorth Monitor

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - The Daily Press

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - Pembroke Observer

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - Strathroy Age Dispatch

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - Chatham-Kent This Week

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - Sarnia and Lambton County This Week

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - The Intelligencer

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - Post Register

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - StockTitan

Sep 26, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - Timmins Times

Sep 26, 2024

Sep 18, 2024

Citizens Financial Group Inc. RI Buys New Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat

Sep 18, 2024

Abcellera stock hits 52-week low at $2.4 amid market challenges - Investing.com Canada

Sep 06, 2024

Abcellera stock hits 52-week low at $2.4 amid market challenges - Investing.com UK

Sep 06, 2024

Sep 03, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Consensus Price Target from Analysts - MarketBeat

Sep 03, 2024

Sep 01, 2024